Pheochromocytoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pheochromocytoma – Pipeline Review, H2 2016’, provides an overview of the Pheochromocytoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pheochromocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pheochromocytoma

The report reviews pipeline therapeutics for Pheochromocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pheochromocytoma therapeutics and enlists all their major and minor projects

The report assesses Pheochromocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pheochromocytoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pheochromocytoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pheochromocytoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Exelixis, Inc.

MediaPharma s.r.l.

Pfizer Inc.

Progenics Pharmaceuticals, Inc.

Valeant Pharmaceuticals International, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pheochromocytoma Overview 6

Therapeutics Development 7

Pipeline Products for Pheochromocytoma - Overview 7

Pipeline Products for Pheochromocytoma - Comparative Analysis 8

Pheochromocytoma - Therapeutics under Development by Companies 9

Pheochromocytoma - Therapeutics under Investigation by Universities/Institutes 10

Pheochromocytoma - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Pheochromocytoma - Products under Development by Companies 13

Pheochromocytoma - Products under Investigation by Universities/Institutes 14

Pheochromocytoma - Companies Involved in Therapeutics Development 15

Exelixis, Inc. 15

MediaPharma s.r.l. 16

Pfizer Inc. 17

Progenics Pharmaceuticals, Inc. 18

Valeant Pharmaceuticals International, Inc. 19

Pheochromocytoma - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 28

cabozantinib s-malate - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

iobenguane sulfate I 131 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

LMP-400 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

metyrosine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

MPBF-001 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

S-43126 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

sunitinib malate - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Pheochromocytoma - Dormant Projects 59

Pheochromocytoma - Product Development Milestones 60

Featured News & Press Releases 60

Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra 60

Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015 60

Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma 61

Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015 61

Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma 61

Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma 62

Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications 63

Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas 63

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

List of Tables

Number of Products under Development for Pheochromocytoma, H2 2016 7

Number of Products under Development for Pheochromocytoma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Pheochromocytoma – Pipeline by Exelixis, Inc., H2 2016 15

Pheochromocytoma – Pipeline by MediaPharma s.r.l., H2 2016 16

Pheochromocytoma – Pipeline by Pfizer Inc., H2 2016 17

Pheochromocytoma – Pipeline by Progenics Pharmaceuticals, Inc., H2 2016 18

Pheochromocytoma – Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 27

Pheochromocytoma – Dormant Projects, H2 2016 59

List of Figures

List of Figures

Number of Products under Development for Pheochromocytoma, H2 2016 7

Number of Products under Development for Pheochromocytoma – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Top 10 Targets, H2 2016 21

Number of Products by Stage and Top 10 Targets, H2 2016 21

Number of Products by Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Stage and Top 10 Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports